MaxCyte Investor Presentation Deck

MaxCyte: Leading Partner for Complex Cellular Engineering 75+ Potential SPL Partnerships Current addressable market** **Number of gene-modified ex- vivo cell therapy companies using non-viral delivery. invios INNOVATIVE IMMUNO-ONCOLOGY editas MEDICINE 24 Beam THERAPEUTICS Kite A GILEAD Company CARIBOU BIOSCIENCES VERTEX 24 SPL Partnerships signed since 2017 KSQ MYELCID prime Therapeutics, Inc. medicine_ Strategic Platform Licenses (SPL) Partnerships, including 5 in 2023 and 1 in 2024 PRECISION BIOSCIENCES Allogene CO celularity THERAPEUTICS 125+ Programs* Clinical Licenses that are part of our SPLs CRISPRI THERAPEUTICS Sana Biotechnology VOR BIOPHARMA nkarta THERAPEUTICS INTIMA BIOSCIENCE LION TCR WE HUNT VIRUSES M MaxCyte *Updated as of December 31, 2022 curamys 16 Programs are currently active in the clinic* LG Chem Cleared INDS or Equivalent WALKING FISH THERAPEUTICS Lyell Immunopharma catamaranBIO VITTORIA biotherapeutics © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation